Landmark study data will determine Asarina's future: "We are on the edge of our seats"
In two weeks' time, Swedish company Asarina Pharma will find out whether its drug candidate has passed the test of a large phase II study within its key indication. The result will define the company's future, says Danish CEO Peter Norkild.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
Nerves are being tested at Swedish biotech firm Asarina Pharma, which has a Dane, Peter Norkild, as CEO.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
